1 |
S. Meisel, A. Shamiss and T. Rosenthal, Clinical pharmacokinetics of ramipril, Clin. Pharmacokinet., 26(1), 7-15 (1994)
DOI
ScienceOn
|
2 |
식품의약품안전청 고시 제 2005-31호(2005. 6. 7). 생물학적 동등성시험 기준
|
3 |
X. Y. Lu, J. Z. Shen-Tu and J. Liu, High-performance liquid chromatography-mass spectrometric analysis of ramipril and its active metabolite ramiprilat in human serum: application to a pharmacokinetic study in the Chinese volunteers, J. Pharm. Biomed. Anal., 40(2), 478-483 (2006)
DOI
ScienceOn
|
4 |
N. Bender, B. Rangoonwala, J. Rosenthal and D. Vasmant, Physicochemical and enzyme binding kinetic properties of a new angiotensin-converting enzyme inhibitor ramipril and their clinical implications, Clin. Physiol. Biochem., 8(Suppl 1), 44-52 (1990)
|
5 |
G. T. Warner and C. M. Perry, Ramipril: a review of its use in the prevention of cardiovascular outcomes, Drugs, 62(9), 1381-1405 (2002)
DOI
ScienceOn
|
6 |
M. J. Rokoss and K. K. Teo, Ramipril in the treatment of vascular diseases, Expert Opin. Pharmacother., 6(11), 1911-1919 (2005)
DOI
ScienceOn
|
7 |
J. M. van Griensven, R. C. Schoemaker, A. F. Cohen, H. G. Luus, M. Seibert-Grafe and H. J. Röthig, Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril, Eur. J. Clin. Pharmacol., 47(6), 513-518 (1995)
DOI
|
8 |
Z. Zhu, A. Vachareau and L. Neirinck, Liquid chromatography- mass spectrometry method for determination of ramipril and its active metabolite ramiprilat in human plasma, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 779(2), 297-306 (2002)
DOI
ScienceOn
|
9 |
K-BE Test 2002 for Window, Y. J. Lee, S. J. Jung and C. K. Shim, Version 1.2.1. (2002)
|
10 |
V. R. Anderson, C. M. Perry and D. M. Robinson, Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients, Am. J. Cardiovasc. Drugs, 6(6), 417-432 (2006)
DOI
ScienceOn
|